National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.
Chiba University Hospital, Chiba, Japan.
Trials. 2021 Mar 12;22(1):204. doi: 10.1186/s13063-021-05143-6.
Incomplete clinical trials for pediatric drug development result in a lack of adequate scientific evidence for providing appropriate medication to pediatric populations; this is especially true for Japan. Thus, using the European Clinical Trials Database (EudraCT), this study aimed to identify the factors related to the study design and administration that lead to incompletion of clinical trials that included pediatric patients.
We focused on clinical trials that included patients under the age of 18 registered in the database, named as the European Clinical Trials Database between January 1, 2014, and December 31, 2018. Two groups of trials were identified: "all cases completed" and "not all cases completed," reflecting whether they were completed in all participating countries/regions or not. To identify the factors of the occurrence of "not all cases completed," a logistic regression analysis was performed to calculate the odds ratios and 95% confidence intervals. In total, 142 clinical trials (95 "all cases completed" and 47 "not all cases completed") were analyzed.
The logistic regression analysis showed the number of countries in which a clinical trial was conducted to be the only significant factor (odds ratio: 1.3; 95% confidence interval: 1.1-1.5); this was identified as the primary factor for the occurrence of "not all cases completed" in the clinical trials that included pediatric patients.
Our findings suggest that the feasibility of clinical trials that include pediatric patients, such as whether the countries in which the trial is to be conducted are suitable, must be considered prior to the trial.
儿科药物开发的临床试验不完整导致缺乏为儿科人群提供适当药物的充分科学证据;日本尤其如此。因此,本研究利用欧洲临床试验数据库(EudraCT),旨在确定与研究设计和管理相关的因素,这些因素导致包含儿科患者的临床试验无法完成。
我们专注于在数据库中注册的年龄在 18 岁以下的患者的临床试验,这些临床试验被命名为 2014 年 1 月 1 日至 2018 年 12 月 31 日期间的欧洲临床试验数据库。确定了两组试验:“所有病例均完成”和“并非所有病例均完成”,反映了它们是否在所有参与国家/地区完成。为了确定“并非所有病例均完成”发生的因素,进行了逻辑回归分析,以计算优势比和 95%置信区间。总共分析了 142 项临床试验(95 项“所有病例均完成”和 47 项“并非所有病例均完成”)。
逻辑回归分析表明,临床试验进行的国家数量是唯一的重要因素(优势比:1.3;95%置信区间:1.1-1.5);这被认为是包含儿科患者的临床试验中发生“并非所有病例均完成”的主要因素。
我们的研究结果表明,在进行临床试验之前,必须考虑包含儿科患者的临床试验的可行性,例如将要进行试验的国家是否合适。